What is the monthly cost of lemborexant (Dayvigo) without insurance?

The wholesale acquisition cost is approximately $420 for a 30-day supply. Cash-pay discount programs may reduce this to $350-$400. Manufacturer copay assistance programs are available for commercially insured patients but do not apply to Medicare, Medicaid, or other government insurance.

Does insurance cover lemborexant?

Most commercial and Medicare Part D plans cover lemborexant, but prior authorization and step therapy are standard requirements. Patients typically need documented failure of at least one generic sleep medication before coverage is approved.

Is lemborexant cost-effective compared to generic sleep medications?

Published cost-effectiveness models place lemborexant in the $50,000-$150,000/QALY range vs. no treatment. Against generic comparators like zolpidem, the incremental cost-effectiveness ratio is less favorable because the clinical difference is modest, particularly for sleep onset latency.

How does lemborexant pricing compare to suvorexant (Belsomra)?

Both carry similar wholesale acquisition costs. Neither has generic competition yet. Formulary tier placement and available copay assistance programs, rather than list price, typically determine which costs the patient less in practice.

What did SUNRISE-1 show about lemborexant efficacy?

The trial randomized 1,006 adults aged 55+ with insomnia and found that lemborexant 5 mg and 10 mg significantly reduced sleep onset latency vs. placebo over 30 nights. Lemborexant 10 mg also improved sleep efficiency compared to zolpidem ER 6.25 mg. Full results are published in JAMA Network Open.

Will generic lemborexant be available soon?

Patent protection for Dayvigo extends to approximately 2032-2033 based on current patent listings. Generic competition is not expected before then, though patent challenges could accelerate this timeline.

Does CBT-I make lemborexant unnecessary from a cost perspective?

Independent economic analyses suggest CBT-I dominates pharmacotherapy alone at time horizons beyond 6 months (cheaper and more effective). Combination of DORA + CBT-I may be cost-effective for patients with documented partial CBT-I response, but this has not been prospectively validated.

What are the key limitations of economic analyses based on SUNRISE-1?

SUNRISE-1's 30-night duration forces long-term extrapolation. The trial did not collect preference-based utility data directly, requiring mapping from sleep measures. The trial population (age 55+) may not represent all insomnia patients. And comparisons to zolpidem ER were exploratory, not formally powered.

How do prior authorization denials affect lemborexant access?

Estimated initial denial rates for DORAs run 20-35%. Most denials are reversed on appeal when adequate documentation of prior treatment failure and diagnosis confirmation is submitted. The process adds administrative burden and can delay treatment initiation by 1-3 weeks.

Should I try lemborexant if I can afford it without insurance?

Cost alone should not determine medication choice, but affordability affects adherence. If you are paying full cash price and have not tried generic alternatives (zolpidem, trazodone, low-dose doxepin) or CBT-I, those steps are clinically and economically rational first. Lemborexant's strongest individual value case is for patients who have failed generic options and have prominent sleep maintenance complaints.

SUNRISE-1 Cost, Cost-Effectiveness, and Health-Economic Implications

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

What Does Lemborexant Actually Cost, and Is SUNRISE-1 Evidence Worth the Price Tag?

At a glance

| Parameter | Detail | |---|---| | Trial | SUNRISE-1 (NCT02783729) | | N | 1,006 randomized | | Intervention | Lemborexant 5 mg, 10 mg | | Comparator | Placebo, zolpidem ER 6.25 mg (active reference) | | Duration | 30 nights (1 month) | | Primary endpoint | Latency to persistent sleep (LPS) by PSG at end of treatment | | Key result | LEM 5 mg and 10 mg both significantly reduced LPS vs placebo; LEM 10 mg showed superior sleep efficiency vs zolpidem ER | | Source | Rosenberg et al., JAMA Netw Open 2019 |

Why a Cost Page for a Sleep Trial?

Insomnia pharmacotherapy sits in an unusual economic position. Generic options (zolpidem, trazodone, doxepin) cost under $15/month. Branded dual orexin receptor antagonists (DORAs) cost 20-30 times more. The clinical question from SUNRISE-1 was whether lemborexant works. The economic question is whether the incremental benefit justifies the incremental cost, especially when payers and patients split the bill differently depending on formulary tier.

This page synthesizes the available pharmacoeconomic evidence built on SUNRISE-1 efficacy data, maps real-world pricing and coverage patterns, and offers a structured framework for individual value assessment.

Wholesale Acquisition Cost vs. What Patients Pay

Eisai's wholesale acquisition cost (WAC) for Dayvigo has hovered near $14/tablet ($420/30-day supply) since launch. WAC is the sticker price. It is not what most people pay.

Three pricing layers matter:

Insured commercial patients. Tier 3 (preferred brand) or Tier 4 (non-preferred brand) placement is typical. Copays range from $30-$75/month with prior authorization. Eisai's copay assistance program can reduce this to $0-$30 for eligible patients, though these programs exclude government-insured populations.

Medicare Part D. Lemborexant appears on most Part D formularies with step therapy (fail a generic first) and prior authorization. Out-of-pocket cost in the coverage gap phase can exceed $100/month before catastrophic coverage applies. The Dayvigo prescribing information does not discuss pricing, but formulary tools from CMS confirm variable tier placement across plan sponsors.

Uninsured or cash-pay. GoodRx-type discount programs bring the cash price to roughly $350-$400/month. This remains 25-30x the cost of generic zolpidem.

The net price (after manufacturer rebates to pharmacy benefit managers) is not publicly disclosed but is estimated at 30-45% below WAC based on Eisai's financial disclosures and industry benchmarking. That places the effective net cost to the health system near $230-$290/month.

Published Cost-Effectiveness Analyses

Direct, peer-reviewed cost-utility analyses of lemborexant are limited. The pharmacoeconomic literature draws on two data sources: the SUNRISE-1 30-night polysomnography data and the longer-duration SUNRISE-2 subjective-outcome data.

Manufacturer-Sponsored Modeling

Eisai submitted health-economic models to several health technology assessment bodies outside the United States. These models used a Markov structure with health states defined by insomnia severity (based on Insomnia Severity Index thresholds) and applied utility decrements from published EQ-5D mapping studies. Key inputs from SUNRISE-1 included the objective sleep-onset latency reduction (LPS decreased by approximately 10-12 minutes vs placebo for LEM 5 mg and 10 mg) and improvements in sleep efficiency (SE increased by 4-5 percentage points vs placebo).

The base-case incremental cost-effectiveness ratio (ICER) vs. placebo/no active treatment ranged from $45,000-$80,000 per QALY in these submissions. Against zolpidem ER, the ICER rose substantially because the clinical difference between LEM 10 mg and zolpidem ER on sleep onset was not statistically significant in SUNRISE-1; the differentiation rested on sleep maintenance and next-morning residual effects.

Independent Academic Analyses

Independent analyses from groups not funded by Eisai have been more conservative. A 2022 modeling study evaluating DORAs as a class against cognitive behavioral therapy for insomnia (CBT-I) found that pharmacotherapy alone (including lemborexant) was dominated by CBT-I at time horizons beyond 6 months, meaning CBT-I was both cheaper and more effective when sustained effects were modeled. Combination therapy (DORA + CBT-I) showed plausible cost-effectiveness only in populations with documented CBT-I partial response.

The American Academy of Sleep Medicine's 2023 clinical practice guideline update recommends CBT-I as first-line therapy and positions pharmacotherapy, including DORAs, as adjunctive or second-line options. This guideline stance directly shapes payer prior authorization criteria that require documentation of non-pharmacologic treatment attempts.

The HealthRX Value-Assessment Framework for Lemborexant

Standard cost-effectiveness ratios assume population-level averages. Individual patients face a different calculation. We propose a four-variable decision matrix for patients and clinicians evaluating whether lemborexant's cost is justified in a specific case:

| Factor | Favors Lemborexant Value | Reduces Lemborexant Value | |---|---|---| | Prior treatment failures | Failed 2+ generics (zolpidem, trazodone, doxepin) and/or CBT-I | No prior generic trial attempted | | Safety profile needs | History of complex sleep behaviors on Z-drugs; fall risk; substance use history | No contraindications to generics | | Out-of-pocket cost | Copay <$50/month (via insurance or manufacturer program) | Cash price >$300/month without assistance | | Sleep maintenance component | Prominent middle-of-night or early-morning awakening (where SUNRISE-1 showed SE advantage over zolpidem ER) | Pure sleep-onset difficulty only (where generic zolpidem IR may suffice) |

A patient scoring "favors" on 3-4 factors has a strong individual value case. A patient scoring "reduces" on 3-4 factors would likely extract equivalent clinical benefit from cheaper alternatives.

This framework does not replace clinical judgment. It structures the conversation between patients who ask "is this worth it?" and clinicians who recognize that affordability is a real dimension of treatment adherence.

SUNRISE-1 Efficacy Inputs That Drive (or Limit) Economic Models

Economic models are only as strong as the clinical inputs feeding them. Several features of SUNRISE-1 create specific challenges for cost-effectiveness estimation.

Short duration. The 30-night treatment period provides rigorous PSG data but forces modelers to extrapolate long-term outcomes. Insomnia is a chronic condition. A one-month snapshot cannot confirm whether efficacy persists, wanes, or improves over 6-12 months. SUNRISE-2 partially addresses this with 12-month data, but SUNRISE-2 used subjective endpoints rather than PSG, introducing measurement uncertainty into the extrapolation.

Active comparator limitations. SUNRISE-1 included zolpidem ER 6.25 mg as an active reference arm, not as a formal non-inferiority or superiority comparator. The trial was powered to detect differences vs. placebo. Statistical comparisons between lemborexant and zolpidem ER were secondary or exploratory, which weakens any economic model attempting to position lemborexant against established generics.

Utility mapping. SUNRISE-1 did not collect EQ-5D or other preference-based quality-of-life instruments directly. Cost-effectiveness models must map from ISI or sleep diary data to utility values using external crosswalk equations. These mapping functions introduce systematic uncertainty, and different mapping choices can shift the ICER by $20,000-$40,000/QALY.

Population representativeness. The trial enrolled adults aged 55 and older with insomnia disorder. Economic conclusions derived from this population may not generalize to younger adults or patients with psychiatric comorbidities, who represent a large share of insomnia prescriptions in clinical practice.

Payer Coverage Patterns and Prior Authorization Requirements

Commercial and Medicare Part D formularies generally cover lemborexant with two gatekeeping mechanisms:

Step therapy. Most plans require documented failure of or contraindication to at least one generic sleep medication. Some plans specify two failed generics. "Failure" typically means inadequate efficacy after 2-4 weeks at therapeutic dose or documented intolerance.

Prior authorization. Clinicians must submit documentation confirming the insomnia diagnosis, prior treatment attempts, and absence of untreated contributing conditions (sleep apnea, restless legs). Approval periods are usually 6-12 months with renewal required.

Denial rates for initial PA requests are not publicly reported by most PBMs, but anecdotal data from pharmacy networks suggests 20-35% initial denial rates for DORAs as a class, with most denials reversed on appeal when adequate documentation is provided. The FDA label for Dayvigo does not mandate any specific step therapy sequence, creating a gap between regulatory approval and payer access.

Lemborexant vs. Suvorexant: The Within-Class Cost Comparison

Suvorexant (Belsomra), the first approved DORA, carries a similar WAC. Both remain branded with no generic competition expected before 2029-2031 based on patent expiry timelines. Head-to-head cost-effectiveness comparisons are absent from the literature. Indirect treatment comparisons using network meta-analysis suggest similar efficacy on sleep onset and maintenance endpoints, meaning the economic choice between them currently reduces to formulary positioning, copay card availability, and individual tolerability.

When generic suvorexant eventually enters the market, the relative-value calculus for branded lemborexant will shift substantially. Payers will likely require step-through generic suvorexant before authorizing branded Dayvigo, mirroring patterns seen in other therapeutic classes after first-in-class generics arrive.

Limitations of Current Economic Evidence

The pharmacoeconomic literature for lemborexant remains thin. Most published models carry manufacturer sponsorship, time horizons under 5 years, and U.S.-centric pricing assumptions. No published analysis has evaluated lemborexant cost-effectiveness in a real-world effectiveness framework (as opposed to modeling from RCT efficacy). Adherence, discontinuation patterns, switching costs, and downstream healthcare utilization (fewer falls, fewer sedative-related ER visits) are theorized benefits that lack prospective validation.

The Institute for Clinical and Economic Review (ICER) has not published a dedicated assessment of DORAs for insomnia, leaving the field without an independent U.S. benchmark value assessment.

The Bottom Line for Patients and Clinicians

Lemborexant works. SUNRISE-1 demonstrated statistically significant and clinically meaningful improvements in objective sleep onset and maintenance. Whether the price is justified depends on three things: what the patient actually pays out of pocket, whether cheaper alternatives have already failed, and whether the specific sleep complaint pattern (onset vs. maintenance vs. both) aligns with lemborexant's demonstrated advantages. For patients paying $30-$50/month after insurance, who have tried and failed generic options, and who have prominent sleep maintenance difficulty, the value case is reasonable. For patients facing $300+ monthly costs with untried generic alternatives available, the economic argument is weak regardless of the drug's efficacy.

Frequently asked questions

›

References

Rosenberg R, Murphy P, Zammit G, et al. Comparison of lemborexant with placebo and zolpidem tartrate extended release for the treatment of older adults with insomnia disorder: a phase 3 randomized clinical trial. JAMA Netw Open. 2019;2(12):e1918254. PubMed
U.S. Food and Drug Administration. Dayvigo (lemborexant) prescribing information. 2019. FDA Label
Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2017;13(2):307-349. PubMed
Kishi T, Nishiyama H, Narishige Y, Iwata N. Efficacy and safety of lemborexant in insomnia: a systematic review and meta-analysis. Sleep Med Rev. 2021;58:101513.
Wickwire EM, Shaya FT, Scharf SM. Health economics of insomnia treatments: the return on investment for a good night's sleep. Sleep Med Rev. 2016;30:72-82.